A5071798228- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- RNA modifications and cancer
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Lung Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- Genetic factors in colorectal cancer
- DNA Repair Mechanisms
- PI3K/AKT/mTOR signaling in cancer
- MicroRNA in disease regulation
- Extracellular vesicles in disease
- Pancreatic and Hepatic Oncology Research
- Cytokine Signaling Pathways and Interactions
- Microtubule and mitosis dynamics
- Cancer-related Molecular Pathways
- Molecular Biology Techniques and Applications
- BRCA gene mutations in cancer
- Ferroptosis and cancer prognosis
- Quinazolinone synthesis and applications
Hospital Universitario Dexeus
2016-2024
Institut de Recerca Sant Pau
2024
Hospital de Sant Pau
2024
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2023
Weatherford College
2022
USP Institut Universitari Dexeus
2012-2021
MRC Laboratory of Molecular Biology
2017-2021
SOM Biotech (Spain)
2012-2016
Instituto Oncológico Dr. Rosell
2016
Institut Català d'Oncologia
2011-2014
Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib. However, the presence EGFR can only imperfectly predict outcome. We hypothesized that could be influenced both by pretreatment T790M mutation and components DNA repair pathways.We assessed diagnostic specimens from 129 erlotinib-treated advanced NSCLC mutations....
Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can upregulated via interferon gamma (IFN-γ). We have explored whether the expression of IFNG, gene encoding IFN-γ, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role inflammation-associated transcription factors STAT3, IKBKE, STAT1 other genes has also been examined.Total RNA from 17 NSCLC 21 patients was analyzed quantitative reverse...
Abstract Purpose: Concomitant genetic alterations could account for transient clinical responses to tyrosine kinase inhibitors of the EGF receptor (EGFR) in patients harboring activating EGFR mutations. Experimental Design: We have evaluated impact pretreatment somatic T790M mutations, TP53 and Bcl-2 interacting mediator cell death (BCL2L11, also known as BIM) mRNA expression 95 with EGFR-mutant non–small-cell lung cancer (NSCLC) included EURTAC trial (trial registration: NCT00446225)....
// R. Jonas A. Nilsson 1,2,3,* , Niki Karachaliou 4,* Jordi Berenguer 1 Ana Gimenez-Capitan 5 Pepijn Schellen 1,3 Cristina Teixido Jihane Tannous 6 Justine L. Kuiper 7 Esther Drees Magda Grabowska Marte van Keulen Danielle M. Heideman 8 Erik Thunnissen Anne-Marie C. Dingemans 9 Santiago Viteri 4 Bakhos Drozdowskyj 10 Rafael Rosell 4,5,11,12,** Egbert F. Smit 7,** and Thomas Wurdinger 1,3,6,** Cancer Center Amsterdam, Department of Neurosurgery, VU University Medical Center, The Netherlands 2...
Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment. However, virtually all succumb to acquired EGFR resistance that occurs via diverse mechanisms. The diversity and unpredictability of mechanisms presents a challenge for developing new treatments overcome resistance. Here, we show Akt activation is convergent feature resistance, across spectrum diverse, established upstream...
Abstract Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or other acquired are sensitive Aurora B (AURKB) barasertib and S49076. Phospho-histone H3 (pH3), a major product of AURKB, is increased most treatment AURKB reduces levels pH3, triggering G1/S arrest polyploidy. Senescence subsequently induced while, their absence, polyploidy followed...
Anaplastic lymphoma receptor tyrosine kinase (ALK), ROS proto-oncogene 1, (ROS1), and ret (RET) fusions are present in 5%-7% of patients with advanced non-small-cell lung cancer (NSCLC); their accurate identification is critical to guide targeted therapies. FISH immunohistochemistry (IHC) considered the gold standards determine gene fusions, but they have limitations. The nCounter platform a potentially useful genomic tool for multiplexed detection has not been validated clinical...
Despite the diversity of liquid biopsy transcriptomic repertoire, numerous studies often exploit only a single RNA type signature for diagnostic biomarker potential. This frequently results in insufficient sensitivity and specificity necessary to reach utility. Combinatorial approaches may offer more reliable diagnosis. Here, we investigated synergistic contributions circRNA mRNA signatures derived from blood platelets as biomarkers lung cancer detection. We developed comprehensive...
Abstract BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates and may influence response to TKI. We examined mRNA expression of MTOR in 57 patients with -mutant NSCLC from the EURTAC trial. Risk mortality disease progression was lower high compared low/intermediate levels. Analysis further divided into two groups, those having both experiencing shorter overall progression-free survival erlotinib. Validation our...
Intercellular communication is mediated by extracellular vesicles (EVs), as they enclose selectively packaged biomolecules that can be horizontally transferred from donor to recipient cells. Because all cells constantly generate and recycle EVs, provide accurate timed snapshots of individual pathophysiological status. Since blood plasma circulates through the whole body, it often biofluid choice for biomarker detection in EVs. Blood collection easy minimally invasive, yet reproducible...
Breast cancer susceptibility gene 1 (BRCA1) has a central role in chemotherapy-induced DNA damage response. The protein inhibitor of activated STAT (PIAS) family proteins, PIAS1 and PIAS4, are also necessary for adequate repair. To further understand the BRCA1 repair, we examined mRNA expression these genes 133 advanced (stage III-IV) gastric patients using quantitative reverse transcription polymerase chain reaction. All P values were two-sided. median overall survival was 12.5 months (95%...
Abstract EGFR tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC) patients is inevitable. Identification of mechanisms and corresponding targeting strategies can lead to more successful later-line treatment many patients. Using spectrometry-based proteomics, we identified increased fibroblast growth factor receptor 1 (FGFR1) expression Akt activation across erlotinib, gefitinib, osimertinib EGFR-TKI-resistant line models. We show that while combined EGFR-TKI FGFR...
A fraction of sporadic breast cancers has low BRCA1 expression. mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared non-mutation carriers. Furthermore, ovarian cancer patients levels mRNA have longer survival following platinum-based than high mRNA.Tumor biopsies were obtained from 86 who candidates for neoadjuvant chemotherapy, treated four cycles fluorouracil, epirubicin and cyclophosphamide. Estrogen receptor (ER),...
Activation of bypass signaling pathways, impairment apoptosis and mutation epidermal growth factor receptor (EGFR) to a drug-resistant state are well known mechanisms resistance single-agent erlotinib therapy in non-small-cell lung cancer (NSCLC) driven by EGFR mutations. Orphan 1 (ROR1) knockdown inhibited the NCI-H1975 cells (harboring L858R T790M mutations). A pro-survival function for ROR1/MEK/ERK cooperation with AKT has been demonstrated.We have assessed ROR1 expression 45 patients...
The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) harbor EGFR activating mutations in a predominantly Caucasian population. Based on and several Asian trials, anti-EGFR TKIs are standard of care mutation-positive NSCLC. We sought validate rapid multiplex mutation assay companion diagnostic select patients this therapy. Samples from were prospectively screened...
Extracellular vesicles (EVs) are double-layered phospholipid membrane that released by most cells and can mediate intercellular communication through their RNA cargo. In this study, we tested if the NanoString nCounter platform be used for analysis of EV-mRNA. We developed optimized a methodology EV enrichment, EV-RNA extraction analysis. Then, demonstrated validity our workflow analyzing profiles from plasma 19 cancer patients 10 controls developing gene signature to differentiate versus...